Skip to main content
Top
Published in: Seminars in Immunopathology 5/2015

01-09-2015 | Review

Matrix remodeling in systemic sclerosis

Author: Andrew Leask

Published in: Seminars in Immunopathology | Issue 5/2015

Login to get access

Abstract

Systemic sclerosis (SSc, scleroderma) is an often-fatal disease characterized by connective tissue fibrosis of skin and internal organs. In scleroderma, there is an excessive production and accumulation of extracellular matrix (ECM) components resulting from an increase in collagen synthesis and matrix stability. Understanding how this how excessive ECM is produced and remodeled may represent a novel therapeutic approach. In this review, the transcription factors and collagen-modifying enzymes underlying collagen overexpression and enhancing stability in SSc are discussed. Moreover, the role of matrix stiffness in promoting fibrosis via a feed-forward mechanism is discussed. Indeed, the emerging evidence is that enhanced ECM remodeling resulting in increased ECM stiffness may be sufficient in itself to sustain persistence fibrosis in SSc.
Literature
1.
go back to reference Kielty CM, Shuttleworth CA (1997) Microfibrillar elements of the dermal matrix. Microsc Res Tech 38(4):413–427CrossRefPubMed Kielty CM, Shuttleworth CA (1997) Microfibrillar elements of the dermal matrix. Microsc Res Tech 38(4):413–427CrossRefPubMed
2.
go back to reference Yates CC, Hebda P, Wells A (2012) Skin wound healing and scarring: fetal wounds and regenerative restitution. Birth Defects Res C Embryo Today 96(4):325–333PubMedCentralCrossRefPubMed Yates CC, Hebda P, Wells A (2012) Skin wound healing and scarring: fetal wounds and regenerative restitution. Birth Defects Res C Embryo Today 96(4):325–333PubMedCentralCrossRefPubMed
3.
go back to reference Krieg T, Takehara K (2009) Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford) 48(Suppl 3):iii14-8 Krieg T, Takehara K (2009) Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford) 48(Suppl 3):iii14-8
4.
go back to reference Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD (1995) Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 270(7):3423–3428CrossRefPubMed Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD (1995) Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 270(7):3423–3428CrossRefPubMed
5.
go back to reference Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ (2005) Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 7(5):R1113–R1123PubMedCentralCrossRefPubMed Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ (2005) Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 7(5):R1113–R1123PubMedCentralCrossRefPubMed
6.
go back to reference Fleischmajer R, Gay S, Meigel WN, Perlish JS (1978) Collagen in the cellular and fibrotic stages of scleroderma. Arthritis Rheum 21(4):418–428CrossRefPubMed Fleischmajer R, Gay S, Meigel WN, Perlish JS (1978) Collagen in the cellular and fibrotic stages of scleroderma. Arthritis Rheum 21(4):418–428CrossRefPubMed
7.
go back to reference Scharffetter K, Lankat-Buttgereit B, Krieg T (1988) Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 18(1):9–17CrossRefPubMed Scharffetter K, Lankat-Buttgereit B, Krieg T (1988) Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 18(1):9–17CrossRefPubMed
8.
go back to reference Varga J, Bashey RI (1995) Regulation of connective tissue synthesis in systemic sclerosis. Int Rev Immunol 12(2-4):187–199CrossRefPubMed Varga J, Bashey RI (1995) Regulation of connective tissue synthesis in systemic sclerosis. Int Rev Immunol 12(2-4):187–199CrossRefPubMed
9.
go back to reference Saitta B, Gaidarova S, Cicchillitti L, Jimenez SA (2000) CCAAT binding transcription factor binds and regulates human COL1A1 promoter activity in human dermal fibroblasts: demonstration of increased binding in systemic sclerosis fibroblasts. Arthritis Rheum 43(10):2219–2229CrossRefPubMed Saitta B, Gaidarova S, Cicchillitti L, Jimenez SA (2000) CCAAT binding transcription factor binds and regulates human COL1A1 promoter activity in human dermal fibroblasts: demonstration of increased binding in systemic sclerosis fibroblasts. Arthritis Rheum 43(10):2219–2229CrossRefPubMed
10.
go back to reference Bhattacharyya S, Sargent JL, Du P, Lin S, Tourtellotte WG, Takehara K, Whitfield ML, Varga J (2011) Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PLoS One 6(9):e23082PubMedCentralCrossRefPubMed Bhattacharyya S, Sargent JL, Du P, Lin S, Tourtellotte WG, Takehara K, Whitfield ML, Varga J (2011) Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PLoS One 6(9):e23082PubMedCentralCrossRefPubMed
11.
go back to reference Fang F, Ooka K, Bhattacharyya S, Wei J, Wu M, Du P, Lin S, Del Galdo F, Feghali-Bostwick CA, Varga J (2011) The early growth response gene Egr2 (alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses. Am J Pathol 178(5):2077–2090PubMedCentralCrossRefPubMed Fang F, Ooka K, Bhattacharyya S, Wei J, Wu M, Du P, Lin S, Del Galdo F, Feghali-Bostwick CA, Varga J (2011) The early growth response gene Egr2 (alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses. Am J Pathol 178(5):2077–2090PubMedCentralCrossRefPubMed
12.
go back to reference Ponticos M, Papaioannou I, Xu S, Holmes AM, Khan K, Denton CP, Bou-Gharios G, Abraham DJ (2015) Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum 67(1):243–253CrossRef Ponticos M, Papaioannou I, Xu S, Holmes AM, Khan K, Denton CP, Bou-Gharios G, Abraham DJ (2015) Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum 67(1):243–253CrossRef
13.
go back to reference Morris E, Chrobak I, Bujor A, Hant F, Mummery C, Ten Dijke P, Trojanowska M (2011) Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts. Cell Physiol 226(12):3340–3348. doi:10.1002/jcp.22690 CrossRef Morris E, Chrobak I, Bujor A, Hant F, Mummery C, Ten Dijke P, Trojanowska M (2011) Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts. Cell Physiol 226(12):3340–3348. doi:10.​1002/​jcp.​22690 CrossRef
14.
go back to reference Ihn H, Yamane K, Asano Y, Jinnin M, Tamaki K (2006) Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology (Oxford) 45(2):157–165CrossRef Ihn H, Yamane K, Asano Y, Jinnin M, Tamaki K (2006) Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology (Oxford) 45(2):157–165CrossRef
15.
go back to reference Ishida W, Mori Y, Lakos G, Sun L, Shan F, Bowes S, Josiah S, Lee WC, Singh J, Ling LE, Varga J (2006) Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol 126(8):1733CrossRefPubMed Ishida W, Mori Y, Lakos G, Sun L, Shan F, Bowes S, Josiah S, Lee WC, Singh J, Ling LE, Varga J (2006) Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol 126(8):1733CrossRefPubMed
16.
go back to reference Chen Y, Shi-wen X, Eastwood M, Black CM, Denton CP, Leask A, Abraham DJ (2006) Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 54(4):1309–1316CrossRefPubMed Chen Y, Shi-wen X, Eastwood M, Black CM, Denton CP, Leask A, Abraham DJ (2006) Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 54(4):1309–1316CrossRefPubMed
17.
go back to reference Ihn H, Tamaki K (2000) Increased phosphorylation of transcription factor Sp1 in scleroderma fibroblasts: association with increased expression of the type I collagen gene. Arthritis Rheum 43(10):2240–2247CrossRefPubMed Ihn H, Tamaki K (2000) Increased phosphorylation of transcription factor Sp1 in scleroderma fibroblasts: association with increased expression of the type I collagen gene. Arthritis Rheum 43(10):2240–2247CrossRefPubMed
18.
go back to reference Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, Jablonska S, Blaszczyk M, Watson DK, Trojanowska M (2003) Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 163(2):571–581PubMedCentralCrossRefPubMed Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, Jablonska S, Blaszczyk M, Watson DK, Trojanowska M (2003) Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 163(2):571–581PubMedCentralCrossRefPubMed
19.
go back to reference Sandorfi N, Louneva N, Hitraya E, Hajnoczky G, Saitta B, Jimenez SA (2005) Inhibition of collagen gene expression in systemic sclerosis dermal fibroblasts by mithramycin. Ann Rheum Dis 64(12):1685–1691PubMedCentralCrossRefPubMed Sandorfi N, Louneva N, Hitraya E, Hajnoczky G, Saitta B, Jimenez SA (2005) Inhibition of collagen gene expression in systemic sclerosis dermal fibroblasts by mithramycin. Ann Rheum Dis 64(12):1685–1691PubMedCentralCrossRefPubMed
20.
go back to reference Antoniv TT, De Val S, Wells D, Denton CP, Rabe C, de Crombrugghe B et al (2001) Characterization of an evolutionarily conserved far-upstream enhancer in the human α2(I) collagen (COL1A2) gene. J Biol Chem 276:21754–21764CrossRefPubMed Antoniv TT, De Val S, Wells D, Denton CP, Rabe C, de Crombrugghe B et al (2001) Characterization of an evolutionarily conserved far-upstream enhancer in the human α2(I) collagen (COL1A2) gene. J Biol Chem 276:21754–21764CrossRefPubMed
21.
go back to reference Ponticos M, Harvey C, Ikeda T, Abraham D, Bou-Gharios G (2009) JunB mediates enhancer/promoter activity of COL1A2 following TGF-β induction. Nucleic Acids Res 37:5378–5389PubMedCentralCrossRefPubMed Ponticos M, Harvey C, Ikeda T, Abraham D, Bou-Gharios G (2009) JunB mediates enhancer/promoter activity of COL1A2 following TGF-β induction. Nucleic Acids Res 37:5378–5389PubMedCentralCrossRefPubMed
22.
go back to reference Palumbo K, Zerr P, Tomcik M, Vollath S, Dees C, Akhmetshina A, Avouac J, Yaniv M, Distler O, Schett G, Distler JH (2011) The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 70(7):1320–1326CrossRefPubMed Palumbo K, Zerr P, Tomcik M, Vollath S, Dees C, Akhmetshina A, Avouac J, Yaniv M, Distler O, Schett G, Distler JH (2011) The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 70(7):1320–1326CrossRefPubMed
23.
go back to reference Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025–1037CrossRefPubMed Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025–1037CrossRefPubMed
24.
go back to reference Parapuram SK, Shi-wen X, Elliott C, Welch ID, Jones H, Baron M, Denton CP, Abraham DJ, Leask A (2011) Loss of PTEN expression by dermal fibroblasts causes skin fibrosis. J Invest Dermatol 131(10):1996–2003CrossRefPubMed Parapuram SK, Shi-wen X, Elliott C, Welch ID, Jones H, Baron M, Denton CP, Abraham DJ, Leask A (2011) Loss of PTEN expression by dermal fibroblasts causes skin fibrosis. J Invest Dermatol 131(10):1996–2003CrossRefPubMed
25.
go back to reference Wang Y, Fan PS, Kahaleh B (2006) Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 54(7):2271–2279CrossRefPubMed Wang Y, Fan PS, Kahaleh B (2006) Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 54(7):2271–2279CrossRefPubMed
26.
go back to reference Taniguchi T, Asano Y, Akamata K, Noda S, Takahashi T, Ichimura Y, Toyama T, Trojanowska M, Sato S (2015) Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Arthritis Rheum 67(2):517–526CrossRef Taniguchi T, Asano Y, Akamata K, Noda S, Takahashi T, Ichimura Y, Toyama T, Trojanowska M, Sato S (2015) Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Arthritis Rheum 67(2):517–526CrossRef
27.
go back to reference Wu M, Melichian DS, de la Garza M, Gruner K, Bhattacharyya S, Barr L, Nair A, Shahrara S, Sporn PH, Mustoe TA, Tourtellotte WG, Varga J (2009) Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. Am J Pathol 175(3):1041–1055. doi:10.2353/ajpath.2009.090241 PubMedCentralCrossRefPubMed Wu M, Melichian DS, de la Garza M, Gruner K, Bhattacharyya S, Barr L, Nair A, Shahrara S, Sporn PH, Mustoe TA, Tourtellotte WG, Varga J (2009) Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. Am J Pathol 175(3):1041–1055. doi:10.​2353/​ajpath.​2009.​090241 PubMedCentralCrossRefPubMed
28.
go back to reference van der Slot AJ, Zuurmond AM, Bardoel AF, Wijmenga C, Pruijs HE, Sillence DO, Brinckmann J, Abraham DJ, Black CM, Verzijl N, DeGroot J, Hanemaaijer R, TeKoppele JM, Huizinga TW, Bank RA (2003) Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem 278(42):40967–40972CrossRefPubMed van der Slot AJ, Zuurmond AM, Bardoel AF, Wijmenga C, Pruijs HE, Sillence DO, Brinckmann J, Abraham DJ, Black CM, Verzijl N, DeGroot J, Hanemaaijer R, TeKoppele JM, Huizinga TW, Bank RA (2003) Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem 278(42):40967–40972CrossRefPubMed
29.
go back to reference Chanoki M, Ishii M, Kobayashi H, Fushida H, Yashiro N, Hamada T, Ooshima A (1995) Increased expression of lysyl oxidase in skin with scleroderma. Br J Dermatol 133(5):710–715CrossRefPubMed Chanoki M, Ishii M, Kobayashi H, Fushida H, Yashiro N, Hamada T, Ooshima A (1995) Increased expression of lysyl oxidase in skin with scleroderma. Br J Dermatol 133(5):710–715CrossRefPubMed
30.
go back to reference Hinz B (2009) Tissue stiffness, latent TGF-beta1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Curr Rheumatol Rep 11(2):120–126CrossRefPubMed Hinz B (2009) Tissue stiffness, latent TGF-beta1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Curr Rheumatol Rep 11(2):120–126CrossRefPubMed
31.
go back to reference Eckes B, Zweers MC, Zhang ZG, Hallinger R, Mauch C, Aumailley M, Krieg T (2006) Mechanical tension and integrin alpha 2 beta 1 regulate fibroblast functions. J Investig Dermatol Symp Proc 11(1):66–72CrossRefPubMed Eckes B, Zweers MC, Zhang ZG, Hallinger R, Mauch C, Aumailley M, Krieg T (2006) Mechanical tension and integrin alpha 2 beta 1 regulate fibroblast functions. J Investig Dermatol Symp Proc 11(1):66–72CrossRefPubMed
32.
go back to reference Chen Y, Shi-Wen X, van Beek J, Kennedy L, McLeod M, Renzoni EA, Bou-Gharios G, Wilcox-Adelman S, Goetinck PF, Eastwood M, Black CM, Abraham DJ, Leask A (2005) Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 167(6):1699–1711PubMedCentralCrossRefPubMed Chen Y, Shi-Wen X, van Beek J, Kennedy L, McLeod M, Renzoni EA, Bou-Gharios G, Wilcox-Adelman S, Goetinck PF, Eastwood M, Black CM, Abraham DJ, Leask A (2005) Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 167(6):1699–1711PubMedCentralCrossRefPubMed
33.
go back to reference Asano Y, Ihn H, Jinnin M, Mimura Y, Tamaki K (2006) Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma. J Invest Dermatol 126(8):1761–1769CrossRefPubMed Asano Y, Ihn H, Jinnin M, Mimura Y, Tamaki K (2006) Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma. J Invest Dermatol 126(8):1761–1769CrossRefPubMed
34.
go back to reference Shi-wen X, Renzoni EA, Kennedy L, Howat S, Chen Y, Pearson JD et al (2007) Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol 26:625–632CrossRefPubMed Shi-wen X, Renzoni EA, Kennedy L, Howat S, Chen Y, Pearson JD et al (2007) Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol 26:625–632CrossRefPubMed
35.
go back to reference Shi-wen X, Thompson K, Khan K, Liu S, Murphy-Marshman H, Baron M, Denton CP, Leask A, Abraham DJ (2012) Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatology (Oxford) 51(12):2146–2154CrossRef Shi-wen X, Thompson K, Khan K, Liu S, Murphy-Marshman H, Baron M, Denton CP, Leask A, Abraham DJ (2012) Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatology (Oxford) 51(12):2146–2154CrossRef
36.
go back to reference Dooley A, Shi-Wen X, Aden N, Tranah T, Desai N, Denton CP, Abraham DJ, Bruckdorfer R (2010) Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Rheumatology (Oxford) 49(11):2024–2036CrossRef Dooley A, Shi-Wen X, Aden N, Tranah T, Desai N, Denton CP, Abraham DJ, Bruckdorfer R (2010) Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Rheumatology (Oxford) 49(11):2024–2036CrossRef
37.
go back to reference Gerber EE, Gallo EM, Fontana SC et al (2014) Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 503:126–130CrossRef Gerber EE, Gallo EM, Fontana SC et al (2014) Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 503:126–130CrossRef
38.
go back to reference Shiwen X, Stratton R, Nikitorowicz-Buniak J, Ahmed-Abdi B, Ponticos M, Denton C, Abraham D, Takahashi A, Suki B, Layne MD, Lafyatis R, Smith BD (2015) A role of myocardin related transcription factor-A (MRTF-A) in scleroderma related fibrosis. PLoS One 10(5):e0126015PubMedCentralCrossRefPubMed Shiwen X, Stratton R, Nikitorowicz-Buniak J, Ahmed-Abdi B, Ponticos M, Denton C, Abraham D, Takahashi A, Suki B, Layne MD, Lafyatis R, Smith BD (2015) A role of myocardin related transcription factor-A (MRTF-A) in scleroderma related fibrosis. PLoS One 10(5):e0126015PubMedCentralCrossRefPubMed
Metadata
Title
Matrix remodeling in systemic sclerosis
Author
Andrew Leask
Publication date
01-09-2015
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 5/2015
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-015-0508-2

Other articles of this Issue 5/2015

Seminars in Immunopathology 5/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.